Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma
Objective: To explore the potential clinical and prognostic significance of Homo sapiens solute carrier family 35 member F2 (SLC35F2) in the context of lung adenocarcinoma (LUAD). Methods: The expression pattern of SLC35F2 in LUAD tissues and normal tissues was analyzed in The Cancer Genome Atlas (T...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S240584402311036X |
| _version_ | 1797336998162202624 |
|---|---|
| author | Qingzhu Zheng Mingjie Li Yingkun Qiu Jiahao Yang Yingping Cao |
| author_facet | Qingzhu Zheng Mingjie Li Yingkun Qiu Jiahao Yang Yingping Cao |
| author_sort | Qingzhu Zheng |
| collection | DOAJ |
| description | Objective: To explore the potential clinical and prognostic significance of Homo sapiens solute carrier family 35 member F2 (SLC35F2) in the context of lung adenocarcinoma (LUAD). Methods: The expression pattern of SLC35F2 in LUAD tissues and normal tissues was analyzed in The Cancer Genome Atlas (TCGA) datasets and validated in 12 pairs of fresh clinical LUAD tissues and their corresponding adjacent normal tissues using quantitative real-time PCR (qRT-PCR) and western blotting. Immunohistochemistry (IHC) was used to assess the protein expression of SLC35F2 in 60 paraffin-embedded LUAD tissues, and its associations with clinicopathological parameters were further examined. The prognostic significance of SLC35F2 mRNA expression was also evaluated using the Kaplan-Meier method, and Cox regression models in LUAD patients from the TCGA database. The potential utility of SLC35F2 as an indicator of recurrence or metastasis was explored through the follow-up of selected clinical LUAD cases. Lastly, gene set enrichment analysis (GSEA) was conducted to investigate the underlying biological mechanisms and signaling pathways. Results: Bioinformatics analysis utilizing the TCGA database indicated that SLC35F2 mRNA exhibited heightened expression in LUAD tissues when compared to normal tissues. These findings were further substantiated through the examination of 12 pairs of clinical LUAD tissues and their corresponding adjacent normal tissues, employing qRT-PCR and western blotting techniques. IHC results from a cohort of 60 LUAD patients demonstrated an up-regulation of SLC35F2 in 38 out of 60 individuals (63.3 %), which exhibited a significant correlation with tumor size, lymph node metastasis, and clinical stage (all P < 0.05). Both the Kaplan-Meier curve and the Cox proportional hazard analyses indicated a strong association between the up-regulation of SLC35F2 mRNA expression and unfavorable overall survival (OS) in patients with LUAD, as observed in the TCGA datasets (P < 0.05). The follow-up findings from select clinical LUAD cases provided evidence that the expression of SLC35F2 could serve as a dependable biomarker for monitoring the recurrence or metastasis. Additionally, the GSEA highlighted the enrichment of apoptosis, adhesion, small cell lung cancer (SCLC), and p53 signaling pathways in the subgroup of LUAD patients with elevated SLC35F2 expression. Conclusion: SLC35F2 exhibited an up-regulated in both mRNA and protein expression, rendering it a valuable independent prognostic indicator for patients diagnosed with LUAD. |
| first_indexed | 2024-03-08T09:03:01Z |
| format | Article |
| id | doaj.art-e8b7f1ec5b4d41a1854283f1493e762d |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-08T09:03:01Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-e8b7f1ec5b4d41a1854283f1493e762d2024-02-01T06:33:42ZengElsevierHeliyon2405-84402024-01-01101e23828Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinomaQingzhu Zheng0Mingjie Li1Yingkun Qiu2Jiahao Yang3Yingping Cao4Department of Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, ChinaDepartment of Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, ChinaDepartment of Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, ChinaDepartment of Laboratory Medicine, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, 350004, ChinaDepartment of Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, China; Corresponding author. Department of Clinical Laboratory, Fujian Medical University Union Hospital, 29# Xinquan Rd, Fuzhou, 350001, Fujian, China.Objective: To explore the potential clinical and prognostic significance of Homo sapiens solute carrier family 35 member F2 (SLC35F2) in the context of lung adenocarcinoma (LUAD). Methods: The expression pattern of SLC35F2 in LUAD tissues and normal tissues was analyzed in The Cancer Genome Atlas (TCGA) datasets and validated in 12 pairs of fresh clinical LUAD tissues and their corresponding adjacent normal tissues using quantitative real-time PCR (qRT-PCR) and western blotting. Immunohistochemistry (IHC) was used to assess the protein expression of SLC35F2 in 60 paraffin-embedded LUAD tissues, and its associations with clinicopathological parameters were further examined. The prognostic significance of SLC35F2 mRNA expression was also evaluated using the Kaplan-Meier method, and Cox regression models in LUAD patients from the TCGA database. The potential utility of SLC35F2 as an indicator of recurrence or metastasis was explored through the follow-up of selected clinical LUAD cases. Lastly, gene set enrichment analysis (GSEA) was conducted to investigate the underlying biological mechanisms and signaling pathways. Results: Bioinformatics analysis utilizing the TCGA database indicated that SLC35F2 mRNA exhibited heightened expression in LUAD tissues when compared to normal tissues. These findings were further substantiated through the examination of 12 pairs of clinical LUAD tissues and their corresponding adjacent normal tissues, employing qRT-PCR and western blotting techniques. IHC results from a cohort of 60 LUAD patients demonstrated an up-regulation of SLC35F2 in 38 out of 60 individuals (63.3 %), which exhibited a significant correlation with tumor size, lymph node metastasis, and clinical stage (all P < 0.05). Both the Kaplan-Meier curve and the Cox proportional hazard analyses indicated a strong association between the up-regulation of SLC35F2 mRNA expression and unfavorable overall survival (OS) in patients with LUAD, as observed in the TCGA datasets (P < 0.05). The follow-up findings from select clinical LUAD cases provided evidence that the expression of SLC35F2 could serve as a dependable biomarker for monitoring the recurrence or metastasis. Additionally, the GSEA highlighted the enrichment of apoptosis, adhesion, small cell lung cancer (SCLC), and p53 signaling pathways in the subgroup of LUAD patients with elevated SLC35F2 expression. Conclusion: SLC35F2 exhibited an up-regulated in both mRNA and protein expression, rendering it a valuable independent prognostic indicator for patients diagnosed with LUAD.http://www.sciencedirect.com/science/article/pii/S240584402311036XLUADSLC35F2The cancer genome AtlasBiomarkerPrognosis |
| spellingShingle | Qingzhu Zheng Mingjie Li Yingkun Qiu Jiahao Yang Yingping Cao Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma Heliyon LUAD SLC35F2 The cancer genome Atlas Biomarker Prognosis |
| title | Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma |
| title_full | Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma |
| title_fullStr | Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma |
| title_full_unstemmed | Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma |
| title_short | Overexpression of SLC35F2 is a potential prognostic biomarker for lung adenocarcinoma |
| title_sort | overexpression of slc35f2 is a potential prognostic biomarker for lung adenocarcinoma |
| topic | LUAD SLC35F2 The cancer genome Atlas Biomarker Prognosis |
| url | http://www.sciencedirect.com/science/article/pii/S240584402311036X |
| work_keys_str_mv | AT qingzhuzheng overexpressionofslc35f2isapotentialprognosticbiomarkerforlungadenocarcinoma AT mingjieli overexpressionofslc35f2isapotentialprognosticbiomarkerforlungadenocarcinoma AT yingkunqiu overexpressionofslc35f2isapotentialprognosticbiomarkerforlungadenocarcinoma AT jiahaoyang overexpressionofslc35f2isapotentialprognosticbiomarkerforlungadenocarcinoma AT yingpingcao overexpressionofslc35f2isapotentialprognosticbiomarkerforlungadenocarcinoma |